Establishment of the Animal Health Products Wholesale Business as a Separate Reportable Segment, with Revenue and Profit Growth
First written in FY2021. 1 of 17 entries say "Advanced", first in FY2025-H1. Latest entry: FY2026.
No other company in this theme has enough history to compare yet.
- FY2026Updated full-year segment results and reflected the acquisitionAnnual report
「Sales to external customers amounted to ¥12,627 million, compared with ¥11,626 million in the previous fiscal year. Segment profit was ¥304 million, compared with ¥314 million in the previous fiscal year, as the increase in revenue did not fully absorb the higher costs resulting from the subsidiary conversion.」
The veterinary pharmaceutical wholesale business recorded higher revenue, reflecting the conversion of アローメディカル into a consolidated subsidiary, while profit declined due to the resulting increase in costs. - FY2026-H1Interim segment results, reflecting acquisitionAnnual report
「In the wholesale business for veterinary pharmaceuticals, sales increased, partly due to the conversion of アローメディカル㈱ into a consolidated subsidiary, despite the negative impact of product changes as some products shifted to direct sales by manufacturers. Profit declined because the increase in revenue did not fully absorb the higher costs associated with the subsidiary conversion. As a result, sales amounted to ¥6,178 million, or 109.4% of the year-earlier period, and segment profit (operating profit) was ¥108 million, or 75.1% of the year-earlier period.」
Interim results reflecting the conversion of アローメディカル into a consolidated subsidiary have been disclosed. Revenue increased, while profit declined due to higher costs associated with the subsidiary conversion and other factors. - FY2025Full-year results, reflecting acquisitionAnnual report
「Following the conversion of アローメディカル㈱ (headquartered in Yokohama) into a consolidated subsidiary in August 2024, sales to external customers amounted to ¥11,626 million, compared with ¥11,027 million in the previous fiscal year. Segment profit, however, was ¥314 million, down from ¥350 million in the previous fiscal year, due in part to higher purchase prices.」
Full-year results reflecting the conversion of アローメディカル into a consolidated subsidiary have been disclosed. Revenue increased, while profit declined due to higher purchase prices and other factors. - FY2025-H1AdvancedAnnual report
「In the animal health products wholesale business, sales were ¥5,647 million, or 101.0% of the same period of the previous interim fiscal year, despite the negative impact of product changes as some products shifted to direct sales by manufacturers. This also reflected the consolidation of Arrow Medical Co., Ltd. as a subsidiary. Segment profit (operating profit) was ¥144 million, or 78.6%, due to the impact of higher purchase prices and other factors.」
It has updated the interim results for the animal health products wholesale business, including the consolidation of Arrow Medical as a subsidiary. Revenue increased, while profit declined due to higher purchase prices and other factors. - FY2024Updated full-year segment results: increased revenue and slight earnings growthAnnual report
「In the animal health products wholesale business, sales to external customers were ¥11,027 million, compared with ¥10,889 million in the previous fiscal year, and segment profit was ¥350 million, compared with ¥349 million, due in part to growth in the companion animal division.」
It has updated the FY2024 full-year results for the animal health products wholesale business. Revenue increased due to growth in the companion animal division, while profit rose slightly. - FY2024-Q3Third-quarter segment results: increased revenue and earningsAnnual report
「In the animal health products wholesale business, sales in the companion animal division increased, with revenue reaching ¥8,472 million compared with ¥8,164 million in the same period of the previous year, while segment profit (operating profit) was ¥288 million compared with ¥283 million despite the impact of higher purchase prices and other factors.」
The animal health products wholesale business posted higher revenue due to increased sales in the companion animal division, and segment profit exceeded the same period of the previous year despite the impact of higher purchase prices and other factors. - FY2024-Q2Second-quarter segment results: increased revenue and earningsAnnual report
「In the animal health products wholesale business, sales in the companion animal division increased to ¥5,589 million, compared with ¥5,314 million in the same period of the previous year, while segment profit (operating profit) was ¥183 million, compared with ¥182 million, due to the impact of higher purchase prices and other factors.」
The animal health products wholesale business posted higher revenue due to increased sales in the companion animal division, and segment profit slightly exceeded the same period of the previous year despite the impact of higher purchase prices. - FY2024-Q1First-quarter segment results: increased revenue and lower earningsAnnual report
「In the animal health products wholesale business, sales in the companion animal division increased to ¥2,783 million, compared with ¥2,660 million in the same period of the previous year, while segment profit (operating profit) was ¥99 million, compared with ¥121 million, due to the impact of higher purchase prices and other factors.」
The animal health products wholesale business posted higher revenue due to increased sales in the companion animal division, while earnings declined due to higher purchase prices and other factors. - FY2023Full-year segment results updated; profit declinedAnnual report
「In the animal health products wholesale business, sales to external customers increased 4.6% year on year to ¥10,879 million, mainly due to increased sales of pet-related products, but segment profit declined 8.6% to ¥339 million due to the recognition of an allowance for doubtful accounts and other factors.」
The animal health products wholesale business posted higher revenue, while earnings declined due to the recognition of an allowance for doubtful accounts and other factors. - FY2023-Q3Third-quarter segment results: increased revenue and lower earningsAnnual report
「In the animal health products wholesale business, revenue was ¥8,157 million, or 103.9% of the same period of the previous year, due to increased sales of high-margin products, while segment profit (operating profit) was ¥276 million, or 86.6%, due to higher logistics costs.」
The animal health products wholesale business posted higher revenue due to increased sales of high-margin products, while segment profit fell below the same period of the previous year due to higher logistics costs. - FY2023-Q2Second-quarter segment results: increased revenue and lower earningsAnnual report
「In the animal health products wholesale business, revenue was ¥5,309 million, or 103.5% of the same period of the previous year, due to increased sales of high-margin products, while segment profit (operating profit) was ¥178 million, or 94.1%, due to higher logistics costs.」
The animal health products wholesale business posted higher revenue due to increased sales of high-margin products, while segment profit fell below the same period of the previous year due to higher logistics costs. - FY2023-Q1Updated first-quarter segment results and increased revenue and earningsAnnual report
「In the animal health products wholesale business, revenue was ¥2,657 million, or 102.9% of the same period of the previous year, and segment profit (operating profit) was ¥118 million, or 110.7%, due to increased sales of high-margin products.」
The animal health products wholesale business exceeded the same period of the previous year in both revenue and segment profit due to increased sales of high-margin products. - FY2022Full-year segment results updated; profit declinedAnnual report
「In the animal health products wholesale business, sales to external customers increased 6.0% year on year to ¥10,399 million due to the market recovery, but segment profit declined 7.5% to ¥371 million due to higher logistics costs and other factors.」
The animal health products wholesale business posted higher revenue, while full-year segment profit declined due to higher logistics costs and other factors. - FY2022-Q3Updated third-quarter segment results and lower earningsAnnual report
「In the animal health products wholesale business, revenue was ¥7,850 million, or 104.9% of the same period of the previous year, due to the market recovery, while segment profit (operating profit) was ¥318 million, or 97.3%, due to higher outsourced logistics costs and other factors.」
The animal health products wholesale business posted higher revenue due to the market recovery, while segment profit reached 97.3% of the same period of the previous year due to higher outsourced logistics costs and other factors. - FY2022-Q2Updated second-quarter segment results and increased revenue and earningsAnnual report
「In the animal health products wholesale business, revenue was ¥5,128 million, or 105.3% of the same period of the previous year, and segment profit (operating profit) was ¥189 million, or 103.6%, due to the market recovery.」
The animal health products wholesale business posted higher revenue and earnings due to the market recovery, with segment profit reaching 103.6% of the same period of the previous year. - FY2022-Q1Updated first-quarter segment results and increased revenue and earningsAnnual report
「In the animal health products wholesale business, revenue was ¥2,581 million, or 104.5% of the same period of the previous year, and segment profit (operating profit) was ¥106 million, or 130.1%, due to the market recovery.」
The animal health products wholesale business posted higher revenue and earnings due to the market recovery, with segment profit reaching 130.1% of the same period of the previous year. - FY2021First statedAnnual report
「Beginning with the current fiscal year, the Company changed its presentation method and reports the animal health products wholesale business, which had previously been included in Other, as a reportable segment because its quantitative significance had increased. Due in part to the pet boom during the COVID-19 pandemic, sales to external customers were ¥9,811 million, up 1.0% from the previous fiscal year, and segment profit was ¥401 million, up 13.7%.」
The quantitative significance of the animal health products wholesale business increased, and it was presented separately as a reportable segment. Both revenue and segment profit exceeded the previous year.